NYSE$STVN
Stevanato Group S.p.A. · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Stevanato Q2 2025: €280M revenue (+8%), margins expand on high-value syringe demand
Stevanato Group reported second-quarter 2025 results via its August 5 conference call, with revenue of €280 million, up 8% year over year (10% constant currency), driven by 10% growth in Biopharmaceutical & Diagnostic Solutions that offset a 2% decline in Engineering. High-value solutions grew 13% to €116.8 million, representing 42% of total revenue, led by high-value syringes. Consolidated gross margin expanded 210 bps to 28.1%. Net profit totaled €29.7 million (€0.11 diluted EPS); adjusted net profit was €31.3 million with adjusted diluted EPS of €0.11. Adjusted EBITDA rose to €65.1 million with margin of 23.2%, up 240 bps. Management said results keep the company on track for full-year 2025 guidance amid favorable biologics demand and capacity ramp at Latina and Fishers.
- Q2 revenue €280M (+8% YoY, +10% constant currency); BDS up 10% to €243.5M
- High-value solutions €116.8M (+13%), 42% of revenue; gross margin 28.1% (+210 bps)
- Net profit €29.7M; adjusted EBITDA €65.1M (23.2% margin, +240 bps)
- Engineering revenue down 2%; legacy project mix pressured segment margins
- On track for FY25 guidance; vial destocking effects continue to ease
Headline financials
Revenue & EPS history
Stevanato Group · Revenue · Quarterly
€280M
Revenue by segment
Stevanato Group · €518M total across 3 segments · Q4 2025
- Biopharmaceutical and Diagnostic Solutions€307M+9.9%59.3%
- High-value solutions€171M+30.5%33.0%
- Engineering€39.4M-23.0%7.6%
Forward guidance
Management reaffirmed full-year 2025 guidance and raised the high-value solutions mix assumption to 40%–42% of total revenue, while noting a €12–15 million FX headwind on the topline.
Tailwinds
- BDS momentum and margin expansion support FY targets
- Vial demand stabilizing as destocking eases; SAT completions up sharply in H1
Headwinds
- Engineering segment orders forecasted in Q2 shifted to second half 2025
- FX translation headwind of approximately €12–15 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2025
+1.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+3.0%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+22.3%
Q2 2021
Best reaction
-18.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +10.0% | +1.9% | -10.3% | |
| Q3 2025 | -1.7% | -3.3% | -11.6% | |
| Q2 2025 | -9.6% | -7.6% | -9.9% | |
| Q1 2025 | +2.9% | +12.0% | +8.9% | |
| Q4 2024 | +8.6% | +8.8% | +10.5% | |
| Q3 2024 | +16.4% | +12.4% | +3.9% | |
| Q2 2024 | +4.4% | +8.5% | +13.8% | |
| Q1 2024 | -18.9% | -20.7% | -30.8% | |
| Q4 2023 | -11.3% | -14.1% | -12.4% | |
| Q3 2023 | -5.9% | -2.5% | -3.5% | |
| Q2 2023 | +2.5% | +5.6% | +6.3% | |
| Q1 2023 | -3.3% | -1.5% | +2.6% | |
| Q4 2022 | +13.7% | +5.2% | +16.0% | |
| Q3 2022 | +0.4% | +9.1% | +18.0% | |
| Q2 2022 | +4.6% | -3.4% | -5.9% | |
| Q1 2022 | +0.7% | +8.7% | +11.2% | |
| Q4 2021 | -1.4% | -4.2% | +21.9% | |
| Q3 2021 | -8.7% | -11.2% | -4.8% | |
| Q2 2021 | +22.3% | +27.0% | +33.8% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro